Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521538 | 0.92 | HSD11B1 (0.45) | TACR1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL23027974 | 0.91 | HSD11B1 (0.44) | TACR1SLC6A4SLC6A2SLC6A3HSD11B1 | |
| SCHEMBL15820250 | 0.90 | HSD11B1 (0.43) | TACR1SLC6A4HSD11B1 | |
| SCHEMBL5042994 | 0.87 | SLC6A2 (0.53) | TACR1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL28392322 | 0.86 | SLC6A2 (0.46) | TACR1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL4131042 | 0.83 | DCUN1D1 (0.53) | TACR1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL14417237 | 0.81 | SLC6A4 (0.50) | TACR1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL4525149 | 0.81 | GRM2 (0.40) | HSD11B1 | |
| SCHEMBL5037801 | 0.79 | TACR1 (0.45) | TACR1SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL3668795 | 0.79 | SLC6A2 (0.43) | TACR1SLC6A4SLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285664-B2 | Heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments | S.C.R.A.S. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2007-10-23 | — | — | US | disclosed |
| US-20050227991-A1 | New heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-10-13 | — | — | US | disclosed |
| US-6936715-B2 | Lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2005-08-30 | — | — | US | disclosed |
| US-20030105107-A1 | Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines | IPSEN PHARMA S.A.S. (FR) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105107-A1 | Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines | LTC4S, LPO, COASY | TACR1 1917/4885SLC6A4 4658/4885SLC6A2 4429/4885 |
| US-20050227991-A1 | New heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments | LPO, LTC4S, BBOX1 | TACR1 2256/4885SLC6A4 4695/4885SLC6A2 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.